Percheron Therapeutics Ltd - Company Profile

Powered by

All the sales intelligence you need on Percheron Therapeutics Ltd in one solution.

$ $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Percheron Therapeutics Ltd fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Percheron Therapeutics Ltd.

Back to companies

Percheron Therapeutics Ltd: Patents

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

View up-to-date information on Percheron Therapeutics Ltd patents, including inventor and filing insights.

Patent Trends

Publication Identifier Document Type Title Classification-CPC Publication Date
EP3965778A4 Search Report Verfahren zur behandlung von muskeldystrophie mittels inhibitorischer oligonukleotide gegen cd49d C12N15/113; C12N2310/11; C12N2310/315; C12N2310/321; A61K2300/00; A61K31/573; A61K31/58; A61K31/7088; A61K31/7115; A61K31/7125; A61K45/06; A61K48/00; A61P21/00 May 31, 2023
ES2938883T3 Grant Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda C12N15/1138; C12N2310/11; C12N2310/321; C12N2310/322; C12N2310/3341; C12N2310/341; C12N2310/346; C12N2320/30; A61K31/7076; A61K31/7125; A61K45/06; A61P35/02 April 17, 2023
WO2023039643A1 Application Methods and kits therefor C12N15/1138; C12N2310/11; C12N2310/315; C12N2310/321; C12N2310/3341; C12N2310/335; C12N2310/341; C12N2310/342; C12N2320/31; A61K31/573; A61K31/7125; A61K9/0019; A61P21/00; A61P29/00; G01N2333/521; G01N2333/70503; G01N2800/2878; G01N2800/52; G01N33/6893; G01N33/6896 March 23, 2023
CA2811228C Grant Method for reducing circulating leukocytes in a human subject C12N15/1138; C12N2310/11; C12N2310/315; C12N2310/321; C12N2310/322; C12N2310/3341; C12N2310/341; C12N2310/344; C12N2310/346; A61K31/7105; A61K31/7125; A61K35/28; A61K38/193; A61P43/00 March 14, 2023
EP3370734B1 Grant Antisense-oligo zur verwendung bei der behandlung von akuter myeloischer leukämie C12N15/1138; C12N2310/11; C12N2310/321; C12N2310/322; C12N2310/3341; C12N2310/341; C12N2310/346; C12N2320/30; A61K31/7076; A61K31/7125; A61K45/06; A61P35/02 January 04, 2023
Gain a 360-degree view of and make more informed decisions for your business Gain a 360-degree view of and make more informed decisions for your business Learn more

Top Inventors by Filings (Count by publication)

Name Count
Identify the top inventors associated with your target company when you unlock full profile Identify the top inventors associated with your target company when you unlock full profile Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer